New Eli Lilly drug enables up to 23% weight loss
The combination of Zepbound with an experimental amylin treatment shows promising results.
Published 6sem3 sources✓ ConfirmedImportantupdated 6sem
Lire en français
≈ 17s
The fact
Clinical trials aim to improve diabetes and obesity management.
This development could strengthen Lilly’s position in the metabolic treatment market.
3 sources — click a link to read an article on the topic: